Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of ABP-700 for colonoscopy sedation
NL-OMON45846Phase 2Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of moxetomidate in sedation (3 arms), sponsored by The Medicines Company. Primary endpoints: Successful procedure completion by assigned ABP-700 infusion dose, Successful procedure completion with and without bolus adjustment and 11 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
sedation
Beyond the preview
Go deeper on NL-OMON45846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45846.